Found 9 articles for: "Betamethasone Dipropionate"

Efficacy, Convenience, and Safety of Calcipotriene-Betamethasone Dipropionate Cream in Skin of Color Patients With Plaque Psoriasis

July 2023 | Volume 22 | Issue 7 | Original Article | 668 | Copyright © July 2023

Patient Preference for Calcipotriene and Betamethasone Dipropionate Cream Versus Foam for the Topical Treatment of Psoriasis: A Pilot Study

March 2023 | Volume 22 | Issue 3 | Original Article | 271 | Copyright © March 2023

Efficacy and Safety of Calcipotriene/Betamethasone Dipropionate Foam in the Treatment of Psoriasis in Skin of Color

February 2023 | Volume 22 | Issue 2 | Original Article | 165 | Copyright © February 2023

Background: There is a paucity of data on usage of topical medications in patients with darker phototypes. This single-center, randomized, double-blinded, vehicle-controlled clinical ...
Read More

The Maintenance Effect of Calcipotriene 0.05% and Betamethasone Dipropionate 0.064% (Cal/BD) Aerosol Foam in Combination With Apremilast

April 2022 | Volume 21 | Issue 4 | Original Article | 381 | Copyright © April 2022

Even in light of significant recent therapeutic advancements, many patients with psoriasis will use a combination of treatments at some point in the disease course. Despite the frequency with which co...
Read More

Pooled Analysis Demonstrating Superior Patient- Reported Psoriasis Treatment Outcomes for Calcipotriene/ Betamethasone Dipropionate Cream Versus Suspension/Gel

March 2022 | Volume 21 | Issue 3 | Original Article | 242 | Copyright © March 2022

Background: Calcipotriene and betamethasone dipropionate (CAL/BDP) cream is a novel treatment of plaque psoriasis based on PAD™ Technology (PAD-cream) designed to improve patien...
Read More

Adjunctive Use of Calcipotriene 0.005%/Betamethasone Dipropionate 0.064% Foam in Patients With Psoriasis Treated With Ixekizumab

March 2022 | Volume 21 | Issue 3 | Original Article | 235 | Copyright © March 2022

Objective: To examine the effectiveness and safety of adjunctive treatment with calcipotriene 0.005%/betamethasone dipropionate 0.064% (Cal/BD) foam in adult patients with chronic pla...
Read More

Calcipotriene Plus Betamethasone Dipropionate Foam for Mild Psoriasis: Pooled Results from Three Randomized Trials

August 2021 | Volume 20 | Issue 8 | Original Article | 822 | Copyright © August 2021

Background: Psoriasis vulgaris is not easy to manage, even when mild. Knowledge of the efficacy of most topical therapies in this population is limited.
Objective:Read More

Four-Week Daily Calcipotriene/Betamethasone Dipropionate Foam Is Highly Efficacious in Patients With Psoriasis (PSO-LONG Lead-in Phase)

April 2021 | Volume 20 | Issue 4 | Original Article | 436 | Copyright © April 2021

Background: Psoriasis is a chronic disease requiring long-term treatment strategies. Optimal strategies should include initial rapid relief of symptoms followed by long-term managemen...
Read More

A Phase 3, Randomized Trial Demonstrating the Improved Efficacy and Patient Acceptability of Fixed Dose Calcipotriene and Betamethasone Dipropionate Cream

April 2021 | Volume 20 | Issue 4 | Original Article | 420 | Copyright © April 2021

Background: The fixed dose combination of calcipotriene and betamethasone dipropionate (CAL/BDP) is a well-established, efficacious, and safe topical treatment of psoriasis.
Read More